Affiliations: 1 Department of Cell and Developmental Biology, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem 91904, Israel.
2 Alexander Grass Center for Bioengineering, Hebrew University of Jerusalem, Jerusalem, Israel.
Keywords:
yeast, drug, FDA, Alzheimer’s, screen, amyloid beta.
Corresponding Author(s):
Daniel Kaganovich, Department of Cell and Developmental Biology, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem 91904, Israel. dan@cc.huji.ac.il
Triana Amen, Department of Cell and Developmental Biology, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem 91904, Israel; Alexander Grass Center for Bioengineering, Hebrew University of Jerusalem, Jerusalem, Israel. triana.amen@mail.huji.ac.il
Conflict of interest statement:
The authors declare no existing conflicts of interest.
Please cite this article as:
Triana Amen and Daniel Kaganovich (2016). Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization. Microbial Cell 3(3): 97-100. doi: 10.15698/mic2016.03.482
© 2016 Amen and Kaganovich. This is an open-access article released under the terms of the Creative Commons Attribution (CC BY) license, which allows the unrestricted use, distribution, and reproduction in any medium, provided the original author and source are acknowledged.
Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization
Authors:Triana Amen1,2 and Daniel Kaganovich1
doi: 10.15698/mic2016.03.482
Volume 3, pp. 97 to 100, published 03/03/2016.
1 Department of Cell and Developmental Biology, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem 91904, Israel.
2 Alexander Grass Center for Bioengineering, Hebrew University of Jerusalem, Jerusalem, Israel.
Keywords:
yeast, drug, FDA, Alzheimer’s, screen, amyloid beta.
Corresponding Author(s):
Conflict of interest statement:
The authors declare no existing conflicts of interest.
Please cite this article as:
Triana Amen and Daniel Kaganovich (2016). Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization. Microbial Cell 3(3): 97-100. doi: 10.15698/mic2016.03.482
© 2016 Amen and Kaganovich. This is an open-access article released under the terms of the Creative Commons Attribution (CC BY) license, which allows the unrestricted use, distribution, and reproduction in any medium, provided the original author and source are acknowledged.
Abstract: